

# Carolyn D Runowicz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5385235/publications.pdf>

Version: 2024-02-01

100  
papers

11,380  
citations

87843

38  
h-index

38368

95  
g-index

103  
all docs

103  
docs citations

103  
times ranked

12433  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ovarian cancer statistics, 2018. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 284-296.	157.7	2,224
2	Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2727.	3.8	1,499
3	Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1652-1662.	3.0	1,192
4	American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2002, 52, 342-362.	157.7	782
5	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 611-635.	0.8	651
6	American Cancer Society Guidelines for the Early Detection of Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2002, 52, 8-22.	157.7	615
7	Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 696-706.	0.7	560
8	American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 43-73.	157.7	497
9	Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2012, 30, 1553-1561.	0.8	430
10	Association of Tamoxifen and Uterine Sarcoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2758-2760.	0.8	201
11	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	1.4	128
12	Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. <i>Gynecologic Oncology</i> , 2007, 106, 453-460.	0.6	127
13	Pattern of Lymph Node Metastases in Clinically Unilateral Stage I Invasive Epithelial Ovarian Carcinomas. <i>Gynecologic Oncology</i> , 2001, 80, 56-61.	0.6	119
14	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 3152-3165.	0.8	117
15	Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 4460-4468.	3.2	100
16	Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 192, 1230-1237.	0.7	97
17	Platinum Chemotherapy during Pregnancy for Serous Cystadenocarcinoma of the Ovary. <i>Gynecologic Oncology</i> , 1993, 49, 92-94.	0.6	91
18	Preserving Fertility After Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2005, 55, 211-228.	157.7	87

#	ARTICLE	IF	CITATIONS
19	The rectus abdominis myocutaneous flap. , 1998, 83, 510-520.		78
20	Expression of COX-2, Ki-67, Cyclin D1, and P21 in Endometrial Endometrioid Carcinomas. International Journal of Gynecological Pathology, 2002, 21, 147-154.	0.9	67
21	Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma. Gynecologic Oncology, 1989, 34, 395-401.	0.6	65
22	Chemotherapy in Pregnancy. Clinical Obstetrics and Gynecology, 2011, 54, 602-618.	0.6	61
23	Ovarian carcinoma of low malignant potential, infertility, and induction of ovulationâ€”Is there a link?. American Journal of Obstetrics and Gynecology, 1992, 166, 853-854.	0.7	60
24	GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Modern Pathology, 2006, 19, 1429-1436.	2.9	60
25	Taxol in ovarian cancer. Cancer, 1993, 71, 1591-1596.	2.0	59
26	Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial. Menopause, 2011, 18, 17-22.	0.8	56
27	Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment. Gynecologic Oncology, 2010, 119, 451-456.	0.6	55
28	Molecular Screening for Cervical Cancer â€” Time to Give up Pap Tests?. New England Journal of Medicine, 2007, 357, 1650-1653.	13.9	52
29	Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer. International Journal of Gynecological Cancer, 2010, 20, 772-780.	1.2	52
30	Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 2037-2048.	0.8	51
31	Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). American Journal of Obstetrics and Gynecology, 2011, 205, 535.e1-535.e5.	0.7	48
32	Mature Results of a Phase II Trial of Concomitant Cisplatin/Pelvic Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Cervix. Gynecologic Oncology, 1996, 61, 416-422.	0.6	45
33	Catheter complications associated with intraperitoneal chemotherapy. Gynecologic Oncology, 1986, 24, 41-50.	0.6	42
34	A successful term pregnancy following the systemic and intraperitoneal administration of cisplatin chemotherapy. Gynecologic Oncology, 1990, 39, 378-380.	0.6	42
35	Altered expression of transforming growth factor- $\beta$ 21 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. , 1996, 77, 1107-1114.		42
36	A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015. Cancer, 2006, 107, 396-405.	2.0	42

#	ARTICLE	IF	CITATIONS
37	Adenocarcinoma arising in vulvar breast tissue. <i>Cancer</i> , 1988, 62, 2234-2238.	2.0	41
38	Adjuvant therapy for neuroendocrine small cell carcinoma of the cervix: Review of the literature. <i>Gynecologic Oncology</i> , 1991, 43, 167-172.	0.6	41
39	Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix. <i>Cancer</i> , 2003, 97, 1781-1788.	2.0	41
40	American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2003, 7, 67-86.	0.9	41
41	Two fractions of high-dose-rate brachytherapy in the management of cervix cancer: clinical experience with and without chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 702-706.	0.4	38
42	Heterogeneity in hormone receptor status in primary and metastatic endometrial cancer. <i>Gynecologic Oncology</i> , 1990, 38, 437-441.	0.6	34
43	Continuous Low-Dose Combined Hormone Replacement Therapy and the Risk of Endometrial Cancer. <i>Gynecologic Oncology</i> , 1997, 64, 425-430.	0.6	29
44	Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium. <i>Gynecologic Oncology</i> , 2006, 100, 160-165.	0.6	29
45	Promising new therapies in the treatment of advanced ovarian cancer. <i>Cancer</i> , 1995, 76, 2028-2033.	2.0	28
46	A Prospective Randomized Comparison of an Attached Silver-Impregnated Cuff to Prevent Central Venous Catheter-Associated Infection. <i>Gynecologic Oncology</i> , 1995, 58, 92-100.	0.6	28
47	Can Precolposcopy Education Increase Knowledge and Decrease Anxiety?. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 1998, 27, 636-645.	0.2	28
48	A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 326-340.	157.7	28
49	Gynecologic Surveillance of Women on Tamoxifen: First Do No Harm. <i>Journal of Clinical Oncology</i> , 2000, 18, 3457-3458.	0.8	24
50	Lipid-Soluble Antioxidants: Î²-Carotene and Î±-Tocopherol Levels in Breast and Gynecologic Cancers. <i>Gynecologic Oncology</i> , 1994, 55, 72-77.	0.6	23
51	Current Therapies in Ovarian Cancer. <i>Cancer Investigation</i> , 2003, 21, 148-156.	0.6	23
52	Prevalence and Prognostic Role of Triple-Negative Breast Cancer by Race: A Surveillance Study. <i>Clinical Breast Cancer</i> , 2011, 11, 332-341.	1.1	21
53	Ovarian conservation in placental site trophoblastic tumor. <i>Gynecologic Oncology</i> , 1990, 37, 239-243.	0.6	20
54	Allelotype of Papillary Serous Peritoneal Carcinomas. <i>Gynecologic Oncology</i> , 2001, 82, 69-76.	0.6	20

#	ARTICLE	IF	CITATIONS
55	All-trans retinoic acid and interferon- $\gamma$ -2a in patients with metastatic or recurrent carcinoma of the uterine cervix. , 1997, 79, 1574-1580.		19
56	Challenges to National Cancer Instituteâ€œSupported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites. <i>Journal of Oncology Practice</i> , 2010, 6, 114-117.	2.5	19
57	DNA adducts in human and patas monkey material and fetal tissues induced by platinum drug chemotherapy. <i>Reproductive Toxicology</i> , 1994, 8, 207-216.	1.3	18
58	Lymph node sampling in patients with epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 1992, 47, 143-145.	0.6	17
59	Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 120-126.	0.8	17
60	Pelvic exenteration for cervix cancer: Would additional intraoperative interstitial brachytherapy improve survival?. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 38, 143-148.	0.4	16
61	Ovarian Cancer Screening and Early Detection. <i>Women's Health</i> , 2009, 5, 693-699.	0.7	16
62	Lack of Efficacy of Interferon- $\beta$ Therapy in Recurrent, Advanced Cervical Cancer. <i>Journal of Interferon and Cytokine Research</i> , 1995, 15, 1011-1016.	0.5	14
63	Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York Cancer Consortium Study. <i>Gynecologic Oncology</i> , 2010, 116, 442-446.	0.6	14
64	Screening for Gynecologic Malignancies. <i>Surgical Oncology Clinics of North America</i> , 1999, 8, 703-723.	0.6	13
65	Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2007, 120, 55-59.	2.3	13
66	Early detection of abdominal pregnancy by maternal serum AFP+ screening. <i>Prenatal Diagnosis</i> , 1994, 14, 1155-1157.	1.1	12
67	Detection of Human Papillomavirus Type 16 DNA in Peritoneal Washings from Patients with Cervical Carcinoma. <i>Journal of Infectious Diseases</i> , 1987, 155, 1349-1349.	1.9	11
68	Colposcopic and cytologic detection of chronic lymphocytic leukemia. <i>Gynecologic Oncology</i> , 1989, 34, 106-108.	0.6	11
69	Cervical Cancer Screening. <i>Surgical Oncology Clinics of North America</i> , 2005, 14, 777-797.	0.6	11
70	Advances in the screening and treatment of ovarian cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 1992, 42, 327-349.	157.7	10
71	Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1996, 174, 1151-1160.	0.7	10
72	Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 637-642.	0.4	9

#	ARTICLE	IF	CITATIONS
73	The Impact of the Privacy Rule on Cancer Research: Variations in Attitudes and Application of Regulatory Standards. <i>Journal of Clinical Oncology</i> , 2009, 27, 4014-4020.	0.8	9
74	Arterial embolization in the management of abdominal and retroperitoneal hemorrhage. <i>Gynecologic Oncology</i> , 1989, 34, 131-135.	0.6	8
75	CA-125: A potential prognostic indicator in patients with cervical cancer?. <i>Gynecologic Oncology</i> , 1990, 40, 222-224.	0.6	7
76	Profound Thrombocytopenia in Previously Treated Patients with Recurrent Ovarian Carcinoma Receiving Topotecan. <i>Gynecologic Oncology</i> , 1998, 69, 175-176.	0.6	7
77	Office laparoscopy as a screening tool for early detection of ovarian cancer. <i>Journal of Cellular Biochemistry</i> , 1995, 59, 238-242.	1.2	6
78	Gynaecologic effects of tamoxifen. <i>Medical Oncology</i> , 1995, 12, 87-94.	1.2	6
79	Compliance with Papanicolaou Smear Screening Following Tubal Ligation in Women with Cervical Cancer. <i>Journal of Women's Health</i> , 1999, 8, 103-107.	0.9	5
80	Human papillomavirus testing for primary cervical cancer screening. <i>Current Oncology Reports</i> , 2008, 10, 533-537.	1.8	5
81	Can Radiological Procedures Replace Histologic Examination in the Evaluation of Abnormal Vaginal Bleeding?. <i>Obstetrics and Gynecology</i> , 2002, 99, 529-530.	1.2	4
82	Can radiological procedures replace histologic examination in the evaluation of abnormal vaginal bleeding?. <i>Obstetrics and Gynecology</i> , 2002, 99, 529-530.	1.2	4
83	Evaluation of low-dose intraperitoneal interferon- $\beta$ for palliation of ascites in patients with non-ovarian gynecologic malignancies. <i>Gynecologic Oncology</i> , 2003, 89, 420-423.	0.6	4
84	Intraperitoneal Chemotherapy in Ovarian Cancer: An Update. <i>Cancer Journal (Sudbury, Mass )</i> , 2008, 14, 7-9.	1.0	4
85	The assessment of fetal pulmonary maturity by fluorescence polarization (FP-value) of pooled vaginal amniotic fluid associated with ruptured membranes. <i>International Journal of Gynecology and Obstetrics</i> , 1985, 23, 481-488.	1.0	3
86	To P32 or Not to P32, That Is the Question. <i>Gynecologic Oncology</i> , 1993, 50, 139-140.	0.6	3
87	Conservative management of uterine rhabdomyosarcoma. <i>Obstetrics and Gynecology</i> , 1998, 92, 669-670.	1.2	3
88	Fluorescence polarization: Comments on urine contamination. <i>American Journal of Obstetrics and Gynecology</i> , 1981, 139, 613-614.	0.7	2
89	A Critical Assessment of the Role of Second-Look Surgery in Ovarian Carcinoma. <i>Cancer Investigation</i> , 1987, 5, 479-485.	0.6	2
90	CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. <i>American Journal of Obstetrics and Gynecology</i> , 1989, 160, 354-355.	0.7	2

#	ARTICLE	IF	CITATIONS
91	Immune Complexes in ovarian carcinoma. <i>Gynecologic Oncology</i> , 1989, 32, 350-353.	0.6	2
92	Cecal Cancer in a Teenager Presenting with a Pelvic Mass: A Case Report and Review of the Literature. <i>Gynecologic Oncology</i> , 1994, 55, 149-151.	0.6	2
93	THE WISDOM OF HORMONE-REPLACEMENT THERAPY IN SURVIVORS OF OVARIAN AND ENDOMETRIAL CANCER. <i>Surgical Clinics of North America</i> , 2001, 81, 987-993.	0.5	2
94	Surgery – Going to Cut It. Are We Ready?. <i>Gynecologic Oncology</i> , 2002, 84, 357-359.	0.6	2
95	Multimodal therapy in the treatment of vaginal adenocarcinoma arising from endocervicosis. <i>Gynecologic Oncology</i> , 2011, 120, 158-159.	0.6	2
96	Investment in Cancer Control and Research: A Sure Bet. <i>Ca-A Cancer Journal for Clinicians</i> , 2006, 56, 9-10.	157.7	1
97	Clarifying Cancer Mortality Rates. <i>Science</i> , 2006, 313, 171c-172c.	6.0	1
98	Association Between Race/Ethnicity and Survival in Women With Advanced Ovarian Cancer. <i>Cureus</i> , 2021, 13, e16070.	0.2	1
99	Early Diagnosis and Screening for Ovarian Cancer. , 2003, , 219-229.		0
100	The MD CaREs initiative: Tailoring oncology education to ethnically and culturally diverse students.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11019-11019.	0.8	0